Heart & blood pressure · Salt Lake City area, UT
Heart and blood pressure studies in Salt Lake City area, UT
30 recruiting studies have a site in the Salt Lake City area. This page includes nearby cities such as West Valley City, Murray, Sandy, South Jordan.
30 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Salt Lake City, UT + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Salt Lake City, UT + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1
: Vascular Function in Health and Disease
D. Walter Wray
- Location
- Salt Lake City, UT
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
University of Utah
- Location
- Salt Lake City, UT
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
AliveCor
- Location
- Murray, UT + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Murray, UT + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Salt Lake City, UT + 40 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Supira Medical
- Location
- Murray, UT + 24 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- Murray, UT + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Murray, UT + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Salt Lake City, UT + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Eli Lilly and Company
- Location
- Murray, UT + 12 other US sites
- Eligibility basics
- Ages 45–80
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Ogden, UT + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Novartis Pharmaceuticals
- Location
- Murray, UT + 5 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
SoniVie Inc.
- Location
- Salt Lake City, UT + 33 other US sites
- Eligibility basics
- Ages 22–75
- RecruitingPhase 3
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Novartis Pharmaceuticals
- Location
- Salt Lake City, UT
- Eligibility basics
- Ages 2–100
- Recruiting
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
Biosense Webster, Inc.
- Location
- Murray, UT + 9 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
AstraZeneca
- Location
- Salt Lake City, UT + 7 other US sites
- Eligibility basics
- Ages 18–130
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Salt Lake City, UT + 46 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Salt Lake City, UT + 39 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
FORWARD CAD IDE Study
Shockwave Medical, Inc.
- Location
- Salt Lake City, UT + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Salt Lake City, UT + 3 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
A Phase 2 Study of CRD-4730 in CPVT
Cardurion Pharmaceuticals, Inc.
- Location
- Salt Lake City, UT + 4 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Salt Lake City, UT + 46 other US sites
- Eligibility basics
- Ages 50+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.